|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
5
|
|
gptkbp:bfsParent
|
gptkb:Glucophage_XR
gptkb:Riomet
|
|
gptkbp:activities
|
increases insulin sensitivity
decreases hepatic glucose production
|
|
gptkbp:affects
|
vitamin B12 deficiency
bone health concerns
|
|
gptkbp:approves
|
gptkb:FDA
|
|
gptkbp:associated_with
|
hypoglycemia
|
|
gptkbp:brand
|
gptkb:Riomet
gptkb:Fortamet
gptkb:Glucophage
|
|
gptkbp:can_be_used_with
|
gptkb:Company
DPP-4 inhibitors
GLP-1 receptor agonists
sulfonylureas
|
|
gptkbp:category
|
B
|
|
gptkbp:clinical_trial
|
Phase III
|
|
gptkbp:contraindication
|
renal impairment
acute or chronic metabolic acidosis
|
|
gptkbp:developed_by
|
gptkb:Bristol-Myers_Squibb
|
|
gptkbp:discovered_by
|
gptkb:1922
|
|
gptkbp:dosage_form
|
500 mg
1000 mg
extended-release tablet
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:formulation
|
oral tablet
liquid solution
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
metformin hydrochloride
|
|
gptkbp:improves
|
lipid profiles
|
|
gptkbp:increased
|
ovulation rates
|
|
gptkbp:ingredients
|
C4 H11 N5
|
|
gptkbp:interacts_with
|
gptkb:beer
iodinated contrast agents
|
|
gptkbp:is_atype_of
|
A10 B A02
|
|
gptkbp:is_available_on
|
generic medication
|
|
gptkbp:is_used_for
|
type 2 diabetes
|
|
gptkbp:lifespan
|
6 hours
|
|
gptkbp:reduces
|
body weight
|
|
gptkbp:release_region
|
gptkb:Australia
gptkb:India
gptkb:United_Kingdom
gptkb:United_States
gptkb:Native_American_tribe
|
|
gptkbp:side_effect
|
lactic acidosis
gastrointestinal upset
|
|
gptkbp:suitable_for
|
severe heart failure
severe liver disease
type 1 diabetes
diabetic ketoacidosis
|
|
gptkbp:treatment
|
polycystic ovary syndrome
|
|
gptkbp:type_of
|
657-24-9
|